Multiomics analyses from large‐scale AD consortia including the Accelerating Medicines Partnership for Alzheimer's Disease (AMP‐AD) and the Target Enablement to Accelerate Therapy Development for AD (TREAT‐AD) have identified PAK1 as a high‐priority target, ranking in the top 3% of genome‐wide targets, with high genetic and multiomics risk scores across multiple AD biodomains.17, 18. Here, PAK1 is linked to Alzheimer disease.